SULFONYLUREAS

Alberti, 1994, A desktop guide for the management of non–insulin-dependent diabetes mellitus (NIDDM): An update, Diabet Med, 11, 899, 10.1111/j.1464-5491.1994.tb00376.x American Diabetes Association, 1995, Consensus statement: The pharmacological treatment of hyperglycemia in NIDDM, Diabetes Care, 18, 1510, 10.2337/diacare.18.11.1510 American Diabetes Association, 1996, Standards of medical care for patients with diabetes mellitus, Diabetes Care, 19, S8, 10.2337/diacare.19.1.S8 Aquilar-Bryan, 1995, Cloning of the β cell high-affinity sulfonylurea receptor: A regulator of insulin secretion, Science, 268, 423, 10.1126/science.7716547 Berger, 1986, Die relative haufigkeit der schweren sulfonylharnstoff-hypoglykamie in den letzten 25 jahren in der Schweiz, Schweiz Med Wochenschr, 116, 145 Borissova, 1991, Factors for development of secondary failure to sulfonylurea drugs in non–insulin-dependent diabetes mellitus, Acta Diabetologica Latina, 28, 91, 10.1007/BF02732118 Boyle, 1993, Octreotide reverses hyperinsulinemia and prevents hypoglycemia induced by sulfonylurea overdoses, J Clin Endocrinol Metab, 76, 752, 10.1210/jc.76.3.752 Chan, 1996, Utilization of antidiabetic drugs in Hong Kong: Relation to the common occurrence of antidiabetic drug-induced hypoglycemia amongst acute medical admissions and the relative prevalence of NIDDM, Int J Clin Pharmacol, 34, 43 Draeger, 1995, Clinical profile of glimepiride, Diabetes Res Clin Pract, 28, S139, 10.1016/0168-8227(95)01072-L Farber, 1990, Acute actions of sulfonylurea drugs during long-term treatment of NIDDM, Diabetes Care, 13, 26, 10.2337/diacare.13.3.26 Farese, 1991, Sulfonylureas activate glucose transport and protein kinase C in rat adipocytes, Metabolism, 40, 196, 10.1016/0026-0495(91)90174-U Fery, 1991, Residual effects of a short-term intensified insulin therapy in type 2 diabetic patients with oral drug failure, Diabete Metab, 17, 525 Geisen, 1988, Special pharmacology of the new sulfonylurea glimepiride, Drug Res, 38, 1120 Groop, 1989, Characteristics of non–insulin-dependent diabetic patients with secondary failure to oral antidiabetic therapy, Am J Med, 87, 183, 10.1016/S0002-9343(89)80695-3 Groop, 1991, Treatment strategies for secondary sulfonylurea failure, Should we start insulin or add metformin? Is there a place for intermittent insulin therapy? Diabete Metab, 17, 218 Groop, 1991, Effect of sulfonylurea on glucose-stimulated insulin secretion in healthy and non–insulin-dependent diabetic subjects: A dose response study, Acta Diabetol, 28, 162, 10.1007/BF00579720 Grunberger, 1993, Continuous versus intermittent sulphonylurea therapy in non–insulin-dependent diabetes mellitus, Drug Saf, 9, 249, 10.2165/00002018-199309040-00002 Harrower, 1994, Comparison of efficacy, secondary failure rate, and complications of sulfonylureas, J Diabetic Complications, 8, 201, 10.1016/1056-8727(94)90044-2 Hod, 1995, Oral hypoglycemic agents as an alternative therapy for gestational diabetes, Isr J Med Sci, 31, 640 Iizuka, 1989, Effect of anti-diabetic treatment on high-density lipoprotein composition and lecithin-cholesterol acyltransferase activity—a comparison between insulin, sulfonylurea and diet alone treatments, Jpn J Med, 28, 457, 10.2169/internalmedicine1962.28.457 Ishibashi, 1990, The effect of timing on gliclazide absorption and action, Hiroshima J Med Sci, 39, 7 Jaber, 1990, An evaluation of the therapeutic effects and dosage equivalence of glyburide and glipizide, J Clin Pharmacol, 30, 181, 10.1002/j.1552-4604.1990.tb03460.x Johnson, 1996, Efficacy of insulin and sulfonylurea combination therapy in type II diabetes: A meta-analysis of the randomized placebo-controlled trials, Arch Intern Med, 156, 259, 10.1001/archinte.1996.00440030049007 Kobayashi, 1996, Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta cell failure in islet cell antibody-positive patients with clinical features of NIDDM, Diabetes, 45, 622, 10.2337/diabetes.45.5.622 Krentz, 1994, Comparative tolerability profiles of oral antidiabetic agents, Drug Saf, 11, 223, 10.2165/00002018-199411040-00002 Lao, 1994, Alcohol tolerance in patients with non–insulin dependent (type 2) diabetes treated with sulfonylurea derivatives, Arzneimittelforschung, 44, 727 Leibowitz, 1996, Sulphonylurea treatment of NIDDM patients with cardiovascular disease: A mixed blessing?, Diabetologia, 39, 503, 10.1007/BF00403296 Loubatieres, 1957, The mechanism of action of the hypoglycemic sulfonamides: A concept based on investigations in animals and human beings, Ann NY Acad Sci, 71, 192, 10.1111/j.1749-6632.1957.tb54591.x Matsuda, 1991, Sulfonylurea enhances insulin-induced acetyl coenzyme A carboxylase activity in rat adipocytes, Horm Metab Res, 23, 209, 10.1055/s-2007-1003655 Melander, 1990, Sulfonylureas: Why, which, and how?, Diabetes Care, 13, 18, 10.2337/diacare.13.3.18 Muller, 1995, Extrapancreatic effects of sulfonylureas—a comparison between glimepiride and conventional sulfonylureas, Diabetes Res Clin Pract, 28, S115, 10.1016/0168-8227(95)01089-V Muller, 1994, Stimulation of glucose utilization in 3T3 adipocytes and rat diaphragm in vitro by the sulfonylureas, glimepiride and glibenclamide, is correlated with modulations of the cAMP regulatory cascade, Biochem Pharmacol, 48, 985, 10.1016/0006-2952(94)90369-7 Muller, 1993, The sulfonylurea drug, glimepiride, stimulates glucose transporter translocation, and dephosphorylation in insulin-resistant rat adipocytes in vitro, Diabetes, 42, 1852, 10.2337/diabetes.42.12.1852 Palmer, 1993, Gliclazide: An update of its pharmacological properties and therapeutic efficacy in non–insulin-dependent diabetes mellitus, Drugs, 46, 92, 10.2165/00003495-199346010-00007 Panten, 1996, Sulfonylurea receptors and the mechanism of sulfonylurea action, Exp Clin Endocrinol Diabetes, 104, 1, 10.1055/s-0029-1211414 Peters, 1991, Insulin plus a sulfonylurea agent for treating type 2 diabetes, Ann Intern Med, 115, 45, 10.7326/0003-4819-115-1-45 Peters, 1996, Maximal dose glyburide therapy in markedly symptomatic patients with type 2 diabetes: A new use for an old friend, J Clin Endocrinol Metab, 81, 2423, 10.1210/jc.81.7.2423 Peters, 1990, Use of sulfonylurea agents in older diabetic patients, Clin Geriatr Med, 6, 903, 10.1016/S0749-0690(18)30588-3 Pugh, 1992, Is combination sulfonylurea and insulin therapy useful in NIDDM patients?, Diabetes Care, 15, 953, 10.2337/diacare.15.8.953 Riddle, 1992, Combined therapy for obese type 2 diabetes: Suppertime mixed insulin with daytime sulfonylurea, Am J Med Sci, 303, 151, 10.1097/00000441-199203000-00003 Robertson, 1993, Problems and pitfalls of sulphonylurea therapy in older patients, Drugs Aging, 3, 510, 10.2165/00002512-199303060-00005 Robertson, 1994, Differentiating glucose toxicity from glucose desensitization: A new message from the insulin gene, Diabetes, 43, 1085, 10.2337/diabetes.43.9.1085 Samanta, 1984, Improved effect of tolbutamide when given before food in patients on long-term therapy, Br J Clin Pharmacol, 18, 647, 10.1111/j.1365-2125.1984.tb02522.x Sartor, 1978, Effects of glipizide and food intake on the blood levels of glucose and insulin in diabetic patients, Acta Med Scand, 203, 211, 10.1111/j.0954-6820.1978.tb14858.x Sartor, 1982, Improved effect of glibenclamide on administration before breakfast, Eur J Clin Pharmacol, 21, 403, 10.1007/BF00542327 Scheen, 1995, Antihyperglycaemic agents: Drug interactions of clinical importance, Drug Saf, 12, 32, 10.2165/00002018-199512010-00003 Seltzer, 1972, A summary of the criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP), Diabetes, 21, 976, 10.2337/diab.21.9.976 Shank, 1995, Bedtime insulin/daytime glipizide: Effective therapy for sulfonylurea failures in NIDDM, Diabetes, 44, 165, 10.2337/diabetes.44.2.165 Shorr, 1996, Individual sulfonylureas and serious hypoglycemia in older people, J Am Geriatr Soc, 44, 751, 10.1111/j.1532-5415.1996.tb03729.x Simpson, 1990, Combination of insulin with glipizide increases peripheral glucose disposal in secondary failure type 2 diabetic patients, Diabetic Med, 7, 143, 10.1111/j.1464-5491.1990.tb01349.x Smith, 1990, Effects of the sulfonylureas on muscle glucose homeostasis, Am J Med, 89, 38S, 10.1016/0002-9343(90)90334-A Smits, 1995, Cardiovascular effects of sulphonylurea derivatives: Implications for the treatment of NIDDM?, Diabetologia, 38, 116, 10.1007/BF02369361 Stryjek-Kaminska, 1989, Analysis of secondary failure to sulfonylureas in type 2 diabetics: A retrospective study for 1976–1987, Diabetes Res Clin Pract, 7, 149, 10.1016/0168-8227(89)90106-X Sugarman, 1991, Hypoglycemia associated hospitalizations in a population with a high prevalence of non–insulin-dependent diabetes mellitus, Diabetes Res Clin Pract, 14, 139, 10.1016/0168-8227(91)90120-3 UK Prospective Diabetes Study Group, 1995, UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: A progressive disease, Diabetes, 44, 1249, 10.2337/diabetes.44.11.1249 University Group Diabetes Program, 1970, A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes II–Mortality results, Diabetes, 19, 789 Wahlin-Boll, 1982, Impaired effect of sulfonylurea following increased dosage, Eur J Clin Pharmacol, 22, 21, 10.1007/BF00606420 Yki-Jarvinen, 1992, Comparison of insulin regimens in patients with non–insulin-dependent diabetes mellitus, N Engl J Med, 327, 1426, 10.1056/NEJM199211123272005 Ziegler, 1994, Hemobiological properties of gliclazide, J Diabetes Complications, 8, 235, 10.1016/1056-8727(94)90050-7